ATAXIA TELANGIECTASIA
Clinical trials for ATAXIA TELANGIECTASIA explained in plain language.
Never miss a new study
Get alerted when new ATAXIA TELANGIECTASIA trials appear
Sign up with your email to follow new studies for ATAXIA TELANGIECTASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
EryDex safety Follow-Up for rare neurological condition ends early
Disease control TerminatedThis study aimed to give continued access to the experimental drug EryDex for people with ataxia telangiectasia, a rare disease affecting movement and coordination. It enrolled 101 patients who had already completed a previous EryDex trial. The main goal was to monitor safety, bu…
Matched conditions: ATAXIA TELANGIECTASIA
Phase: PHASE3 • Sponsor: Quince Therapeutics S.p.A. • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
Experimental drug shows promise for rare childhood movement disorder
Symptom relief TerminatedThis study tested a drug called N-Acetyl-L-Leucine in 17 people with Ataxia-Telangiectasia (A-T), a rare genetic disease that causes severe movement problems. The goal was to see if the drug could safely improve symptoms like coordination and walking. The study was stopped early,…
Matched conditions: ATAXIA TELANGIECTASIA
Phase: PHASE2 • Sponsor: IntraBio Inc • Aim: Symptom relief
Last updated May 15, 2026 11:56 UTC